Pharmaceuticals

Afrezza Market Growth Expected To Reach $464.39 Billion By 2030 At 12.6% CAGR

May 5, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Afrezza Market Expected To Scale Between 2026 And 2030?

The expansion observed in the past period was largely due to a rise in diabetes prevalence, the inherent limitations of injectable insulin, the official clearance of inhaled insulin by regulatory bodies, a strong patient demand for more convenient treatment options, and its swift uptake in adult diabetes management.

The anticipated expansion over the forecast period is due to several factors, including an increasing number of individuals with type 2 diabetes, a greater embrace of inhalation-based drug delivery, the inclusion of more diverse patient demographics, enhancements in pulmonary safety information, and heightened understanding among physicians.

Prominent trends expected during the forecast period involve a greater uptake of inhaled insulin treatments, an increasing desire for needle-free methods in diabetes management, a stronger emphasis on managing post-meal glucose levels, the proliferation of rapid-acting insulin options, and better patient compliance facilitated by convenience.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19863&type=smp

What Leading Drivers Are Supporting The Afrezza Market Expansion?

The expanding incidence of diabetes is anticipated to fuel the expansion of the Afrezza market in the future. Diabetes is a persistent metabolic condition marked by elevated blood sugar, stemming from either inadequate insulin production, diminished insulin efficacy, or a combination of these factors. The surge in diabetes cases is attributed to factors like rising obesity rates, inactive lifestyles, poor dietary habits, an older demographic, increasing urbanization, genetic susceptibility, and enhanced awareness and detection of the illness. Afrezza plays a vital role in managing diabetes by rapidly moderating blood sugar surges after meals, thereby averting complications and facilitating efficient glucose regulation. For example, data from March 2024, provided by the Office for Health Improvement and Disparities, a UK government body, indicated that in March 2023, the proportion of individuals with type 1 diabetes in England who received 8 care processes at GP practices within the NDA framework increased to 43.8%, an ascent from 35.2% recorded in 2022. Consequently, the growing prevalence of diabetes is a key driver for the Afrezza market.

What Are The Key Segment Divisions In The Afrezza Market Segment Structure?

The afrezza market covered in this report is segmented –

1) By Indication: Type 1 Diabetes, Type 2 Diabetes

2) By Distribution Channel: Hospitals And Clinics, Retail Pharmacies, Specialty Pharmacies

3) By End User: Adult Patients, Geriatric Patients

What Trends Are Shaping The Future Of The Afrezza Market?

Major companies operating in the Afrezza market are concentrating on developing technologically advanced products by conducting comprehensive studies concerning the product and diabetes. Afrezza is employed for the management of Type 1 Diabetes utilizing insulin inhalers. For instance, in June 2023, MannKind Corporation, a US-based biopharmaceutical firm, initiated the INHALE-3 study, a clinical trial designed to address a critical unmet need for adults with Type 1 Diabetes. The trial spans 17 weeks and includes a 13-week extension phase, enabling researchers to further evaluate outcomes over an extended duration. INHALE-3 is a randomized, controlled investigation aimed at assessing innovative treatment approaches that could improve daily disease management and overall patient well-being. By launching this trial, MannKind seeks to generate meaningful clinical insights that may support more effective therapeutic options for individuals living with Type 1 Diabetes.

Which Organizations Are Engaged In The Afrezza Market?

Major companies operating in the afrezza market are Mannkind Corporation

Get The Full Afrezza Market Report:

https://www.thebusinessresearchcompany.com/report/afrezza-global-market-report

Where Is The Afrezza Market Primarily Concentrated By Region?

North America was the largest region in the afrezza market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the afrezza market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Afrezza Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/afrezza-global-market-report

Browse Through More Reports Similar to the Global Afrezza Market 2026, By The Business Research Company

Financial Analytics Market Report 2026

https://www.thebusinessresearchcompany.com/report/financial-analytics-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795